Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit

E A Dizdar, C Aydemir, O Erdeve, F N Sari, S Oguz, N Uras, U Dilmen, E A Dizdar, C Aydemir, O Erdeve, F N Sari, S Oguz, N Uras, U Dilmen

Abstract

Palivizumab is currently licensed for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants and children with chronic lung disease, with a history of preterm birth, or with haemodynamically significant congenital heart disease, but its routine use during outbreaks in neonatal intensive care units (NICUs) is not currently recommended. Here we report an outbreak in a NICU detected during a screening trial for RSV infection using a rapid antigen test (Respi-Strip((R))). Eleven preterm infants in our NICU tested positive for RSV during January 2009. Subsequent testing of the remaining infants in the NICU revealed two additional asymptomatic cases. In addition to precautions against cross-infection, palivizumab prophylaxis was administered to the remaining 37 premature infants. Two days after treatment, RSV was detected in two additional infants who had become symptomatic. To our knowledge this is the largest RSV outbreak in a NICU to be identified at an early stage by rapid testing and effectively controlled by infection control measures and palivizumab prophylaxis.

Copyright 2010 The Hospital Infection Society. Published by Elsevier Ltd. All rights reserved.

References

    1. Hall C.B. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344:1917–1928.
    1. MacDonald N.E., Hall C.B., Suffin S.C., Alexson C., Harris P.J., Manning J.A. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med. 1982;307:397–400.
    1. de Sierra T.M., Kumar M.L., Wasser T.E., Murphy B.R., Subbarao E.K. Respiratory syncytial virus-specific immunoglobulins in preterm infants. J Pediatr. 1993;122:787–791.
    1. Policy Statement – Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus ınfections. Pediatrics. 2009;124:1–8.
    1. Cardenas S., Auais A., Piedimonte G. Palivizumab in the prophylaxis of respiratory syncytial virus infection. Expert Rev Anti Infect Ther. 2005;3:719–726.
    1. Bracht M., Heffer M., O'Brien K. Development, implementation, and evaluation of a community- and hospital-based respiratory syncytial virus prophylaxis program. Adv Neonatal Care. 2005;5:39–49.
    1. Kurz H., Herbich K., Janata O., Sterniste W., Bauer K. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units. J Hosp Infect. 2008;70:246–252.
    1. Halasa N.B., Williams J.V., Wilson G.J., Walsh W.F., Schaffner W., Wright P.F. Medical and economic impact of a respiratory syncytial virus outbreak in a neonatal intensive care unit. Pediatr Infect Dis J. 2005;24:1040–1044.
    1. Abadesso C., Almeida H.I., Virella D., Carreiro M.H., Machado M.C. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit. J Hosp Infect. 2004;58:38–41.
    1. Cox R.A., Rao P., Brandon-Cox C. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit. J Hosp Infect. 2001;48:186–192.
    1. Gregson D., Lloyd T., Buchan S., Church D. Comparison of the RSV respi-strip with direct fluorescent-antigen detection for diagnosis of respiratory syncytial virus infection in pediatric patients. J Clin Microbiol. 2005;43:5782–5783.
    1. Forster J., Schumacher R.F. The clinical picture presented by premature neonates infected with the respiratory syncytial virus. Eur J Pediatr. 1995;154:901–905.
    1. Kilani R.A. Respiratory syncytial virus (RSV) outbreak in the NICU: description of eight cases. J Trop Pediatr. 2002;48:118–122.
    1. Heerens A.T., Marshall D.D., Bose C.L. Nosocomial respiratory syncytial virus: a threat in the modern neonatal intensive care unit. J Perinatol. 2002;22:306–307.
    1. Hammer J., Numa A., Newth C.J. Acute respiratory distress syndrome caused by respiratory syncytial virus. Pediatr Pulmonol. 1997;23:176–183.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever